

Table 1. Comparison of cardiovascular disease risk factors and antihypertensive drug using in Both Groups

	Control(n=109)	Observation(n=99)	<i>P</i> value
Age (years), <i>M</i> (95%CI)	50.68(53.03-48.31)	51.92(54.29-49.34)	0.756
Sex, <i>n</i> (%)			
Male	59(54.13)	41(41.41)	0.067
Female	50(45.87)	58(58.59)	
Smoking, <i>n</i> (%)			
Yes	65(59.63)	38 (38.38)	0.770
No	44 (40.37)	61 (61.62)	
Hypertensive History (year), <i>M</i> (95%CI)	5.76(7.37-4.39)	8.40(10.73-6.29)	0.257
Renin Activity (ng/ml/hr), <i>M</i> (95%CI)	3.04(3.89-2.26)	2.246(2.83-1.77)	0.287
Aldosterone (pg/ml), <i>M</i> (95%CI)	66.36(76.12-57.07)	97.99(117.03-79.98)	0.088
ARR, <i>M</i> (95%CI)	6.36(8.29-4.82)	11.12(14.41-8.13)	0.011*
Total Cholesterol (mmol/L), <i>M</i> (95%CI)	4.43(4.61-4.27)	4.39(4.57-4.21)	0.741
TG (mmol/L), <i>M</i> (95%CI)	1.94(2.15-1.75)	1.86(2.04-1.67)	0.875
LDL Cholesterol (mmol/L), <i>M</i> (95%CI)	2.77(2.92-2.61)	2.70(2.86-2.55)	0.451
HDL Cholesterol (mmol/L), <i>M</i> (95%CI)	1.15(1.21-1.10)	1.12(1.18-1.06)	0.828
Creatinine (μmol/L), <i>M</i> (95%CI)	71.31(74.95-67.67)	74.03(81.57-67.92)	0.665
eGFR(ml /	104.09(110.36-97.88)	98.52(105.16-91.66)	0.399

(min*1.73m ²),M(95%C			
I)			
Homocysteine(μmol/L)	15.15(17.34-13.37)	13.72(14.74-12.76)	0.910
,M(95%CI)			
Fasting Glucose	5.14(5.27-5.01)	6.58(8.96-5.39)	0.018*
(mmol/L),M(95%CI)			
2-Hour Postprandial	7.31(7.65-6.99)	7.78(8.34-7.27)	0.406
Glucose			
(mmol/L),M(95%CI)			
Daily Average Salt	8.13(8.85-7.43)	9.67(10.98-8.56)	0.230
Intake (g/d),M(95%CI)			
Number of Anti-hypertensives, n (%)			
Beta-blocker	20(18.34)	19(19.20)	0.876
Calcium Channel	60(55.05)	59(59.60)	0.508
Blocker			
ACEI	11(10.09)	10(10.10)	0.998
ARB	21(19.27)	23 (23.23)	0.484
Diuretic	3(2.75)	9 (9.09)	0.097

Data were displayed as mean (95%CI) or patient numbers with percentages in brackets. All differences in characteristics between groups were non-significant excepting the uric acid and the fasting glucose. * $P < 0.05$ vs. control; two-way analysis of variance.

ARR, Aldosterone-to-Renin Ratio; TG, triglycerides; ACEI, angiotensin-converting enzyme inhibitor ; ARB, angiotensin receptor blockers.

Table 2 Sequences of primers used in PCR

Gene	Sequences (5'-3')
BNP	Forward: TCCTGCTTTTCCTTAATCTGTC
	Reverse:GCTTGAACTATGTGCCATCTTG
β -MHC	Forward: AGGCTCATCCTTTCAGACCG
	Reverse:TCACCCCTGGAGACTTCGT
IKK β	Forward: CAGAAGAGCGAAGTGGACATT
	Reverse:TGAGATTATTGGGGAAGGGT
IKB α	Forward: TGTCTACACTTAGCCTCTATCC
	Reverse:GGGCAACTCATCTTCCGT
NF- κ B p65	Forward: GCAAAAGGACCTACGAGACC
	Reverse:CGGGAAGGCACAGCAATA
GAPDH	Reverse:GACAACTTTGGCATCGTGGA
	Reverse:ATGCAGGGATGATGTTCTGG
